Login to your account

Username *
Password *
Remember Me

Blog With Right Sidebar

    Vous êtes ici :  
  1. Accueil
  2. Blog With Right Sidebar

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Lancet. 2011 May 21;377(9779):1760-9

Authors: Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM,

Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.

PMID: 21571362 [PubMed - indexed for MEDLINE]

Performance of topological texture features to classify fibrotic interstitial lung disease patterns.

Performance of topological texture features to classify fibrotic interstitial lung disease patterns.

Med Phys. 2011 Apr;38(4):2035-44

Authors: Huber MB, Nagarajan MB, Leinsinger G, Eibel R, Ray LA, Wismüller A

Topological texture features were compared in their ability to classify "honeycombing," a morphological pattern that is considered indicative for the presence of fibrotic interstitial lung disease in high-resolution computed tomography (HRCT) images.

PMID: 21626936 [PubMed - indexed for MEDLINE]

Erlotinib or gefitinib for non-small-cell lung cancer.

Erlotinib or gefitinib for non-small-cell lung cancer.

N Engl J Med. 2011 Jun 16;364(24):2367; author reply 2368

Authors: Kaye FJ, Jantz MA, Dallas J

PMID: 21675909 [PubMed - indexed for MEDLINE]

Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.

Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.

Cochrane Database Syst Rev. 2011;5:CD003137

Authors: Ducharme FM, Lasserson TJ, Cates CJ

Asthma patients who continue to experience symptoms despite being on regular inhaled corticosteroids (ICS) represent a management challenge. Long-acting beta(2)-agonists (LABA) or anti-leukotrienes (LTRA) are two treatment options that could be considered as add-on therapy to ICS.

PMID: 21563136 [PubMed - indexed for MEDLINE]

How to set up a severe asthma service.

How to set up a severe asthma service.

Respirology. 2011 Jun 21;

Authors: McDonald VM, Vertigan AE, Gibson PG

Severe asthma affects 5-20% of the asthma population but is discordantly responsible for the major burden of illness and impairment to quality of life. Patients with severe asthma continue to experience ongoing symptoms despite maximal therapy. A severe asthma service provides a systematic approach to the management of the disease and aids in confirming the correct diagnosis, managing co-morbid conditions that may mimic or aggravate asthma, and provides the environment to optimise treatment and asthma self management skills and education. A severe asthma service is also the ideal environment for trialling add on therapies and hence can improve patient outcomes and clinical practice. Within such a service there are many opportunities for training and research. In this article we describe the purpose of a severe asthma clinic, the necessary components of a service including staffing and facilities and the processes for trialling additional therapies used in the management of severe asthma.

PMID: 21692918 [PubMed - as supplied by publisher]

Search

Search